# Bayer Aktiengesellschaft (BAYRY)

> Source: Nexqual · https://nexqual.com/BAYRY · data as of 2026-10-22 19:57 UTC · cite as "Nexqual, Bayer Aktiengesellschaft (BAYRY), nexqual.com/BAYRY" · informational, not investment advice.

**Price:** USD 12.39 (-0.88% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 12.5 · day 12.28–12.4 · 52w 7.48–15.23 · market cap $48.7B · OQX

## Key facts
- 1 of 80 tracked superinvestors hold BAYRY (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 15.9 (range 15.3–16.68).
- Total return with dividends: 1Y +56.3% vs S&P 500 +14.9%; 5Y -4.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.16, revenue estimate $10.00B.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold BAYRY. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Kahn Brothers | Kahn Brothers Group | 13.26% | $74.8M | Unchanged |

## Analysts
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 15.9 (low 15.3, high 16.68).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +56.3% | -4.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +56.5% | -0.9% |
| Volatility (annualized) | 41.5% | 36.8% |
| Max drawdown | -31.2% (Feb 2026→Jun 2026) | -71.4% (May 2022→Dec 2024) |

## Peers (Drug Manufacturers - General)
BIIB (Biogen Inc.) USD 253.84 +5.34% · SNY (Sanofi) USD 41.96 +2.42% · GSK (GSK plc) USD 51.21 +2.38% · BMY (Bristol-Myers Squibb Company) USD 63 +3.08% · PFE (Pfizer, Inc.) USD 30.42 +1.91% · NVO (Novo Nordisk A/S) USD 39.43 +0.95%

## More
Full page: https://nexqual.com/BAYRY · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.16 | $0.16 | +1.1% | $10.00B | 1 |
| Next quarter (ends 2026-12-31) | $0.07 | $0.02 | +232.4% | $11.83B | 1 |
| Current fiscal year (ends 2026-12-31) | $1.28 | $1.16 | +10.2% | $45.87B | 2 |
| Next fiscal year (ends 2027-12-31) | $1.34 | $1.24 | +8.5% | $47.05B | 2 |